FDA Puts Psilocybin and an MDMA Analog on a Two-Month Clock

On April 24, the U.S. Food and Drug Administration issued National Priority Vouchers to three companies developing psychedelic-assisted therapies: Compass Pathways, for its synthetic psilocybin compound COMP360 being tested in treatment-resistant depression; the Usona Institute, for psilocybin in major depressive disorder; and Transcend Therapeutics, for methylone (TSND-201), an MDMA-analog compound being studied for PTSD.

The vouchers are not approvals. They are schedule compressions: the standard 10-to-12-month drug application review window is compressed to one to two months. If the applications land, decisions could come before the end of 2026.

The timing of the April 24 announcement was not incidental. On April 18 — six days earlier — President Trump signed an executive order directing federal agencies to accelerate both the research and approval of psychedelic treatments, and authorized a $50 million investment in state-level psychedelic research programs. Houston Public Media reported on May 5 that Texas was already moving to position itself on the research side. The COMP360, Usona, and Transcend vouchers were among the first concrete output of that directive.

For the substance use disorder treatment field, the question isn’t whether these specific applications will be approved — it’s what approval for any of the three would mean for the broader pipeline. None of the current priority-voucher compounds is indicated specifically for SUD. COMP360 and the Usona psilocybin are studying depression and MDD. TSND-201 is studying PTSD. But the clinical lines are not clean. Treatment-resistant depression and co-occurring PTSD are among the most significant barriers to sustained recovery from substance use disorders, and effective treatments for either condition have documented downstream effects on SUD populations.

Psilocybin’s track record in addiction contexts is already published: Johns Hopkins trials showed significant tobacco cessation outcomes; NYU trials showed durable reductions in alcohol use disorder. Those studies weren’t the basis of the current priority applications — but they inform the field’s expectations about what approval of a psilocybin product, even for depression, would open up in terms of prescribing, research funding, and insurance coverage for SUD-adjacent conditions.

The FDA’s 2024 rejection of Lykos’s MDMA-assisted therapy NDA — it asked for a second Phase 3 trial — made the psychedelic therapy space look stalled. The April 2026 vouchers tell a different story: a different administration, a different priority framework, and a review timeline measured in weeks. The substance use disorder treatment space should be watching closely, because the next approved psychedelic product may create the institutional infrastructure — trained providers, billing codes, payer acceptance — that addiction medicine has been waiting for.

For providers currently seeing patients with co-occurring PTSD and opioid use disorder, or treatment-resistant depression and alcohol use disorder: the clinical picture in this space may change materially before year’s end.